Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: J Clin Immunol. 2014 May 10;34(5):551–554. doi: 10.1007/s10875-014-0051-2

Table 1.

Laboratory evaluation pre- and post-transplantation

At
presentation		 15 months post-
transplantation
ALC (×10^9/L) 28.35 2.06
Eosinophils (×10^9/L) 0.9 0.05
CD3 (cells/uL) 25930 1280
CD4 (cells/uL) 6880 760
CD8 (cells/uL) 17190 450
CD4+CD45RA+CD62L+/CD4+ (%) 0.3 57
CD4+CD45RA−/CD4+ (%) 99.6 37.8
CD8+CD45RA+CD62L+/CD8 (%) 0.3 68
CD8+CD45RA−/CD8+(%) 99.6 26.6
CD3+ TCRab+ (% of CD3+) 99.9 94.7
TCRab+/CD4−CD8−(% of CD3+) 7.3 1.5
CD3+ TCRab−(% of CD3+) 0 5.3
CD19 (cells/uL) 0 80
CD16+56 (cells/uL) 530 640
IgG (mg/dl) 6.9 3.3
IgA (mg/dL) 0.11 0.25
IgM (mg/dl) 0.19 0.5
IgE (kU/L) 29464 464
Proliferative response to PHA (unstimulated/stimulated), expressed as % of CD45+ lymphocytes that were EDU+ (control: 0.3/66.0) 0.1/1.9 0.1/58.3
Proliferative response to anti-CD3 (unstimulated/stimulated) expressed as % of CD45+ lymphocytes that were EDU+ (control: 0.3/28.9) 0.7/0.1 0.2/20.7